Emerging in the arena of obesity treatment, retatrutide represents a distinct method. Unlike many existing medications, retatrutide functions as a dual agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) sensors. This concurrent engagement fosters various helpful effects, like